A Pan-Cancer Analysis of SLC12A5 Reveals Its Correlations with Tumor Immunity

Background. Solute carrier family 12 member 5 (SLC12A5) has been reported to play an oncogenic role in certain malignancies. Its prognostic roles and immune mechanisms of action in human cancers, however, remain largely unknown. Methods. Data derived from TCGA, GEPIA, and TIMER databases were utiliz...

Full description

Saved in:
Bibliographic Details
Published inDisease markers Vol. 2021; pp. 1 - 11
Main Authors Jiang, Yi, Liao, Hong-li, Chen, Li-ya
Format Journal Article
LanguageEnglish
Published United States Hindawi 2021
John Wiley & Sons, Inc
Subjects
Biomarkers
Biomarkers, Tumor - genetics
Cancer
Disease Progression
DNA Mismatch Repair
Gene expression
Gene Expression Profiling - methods
Gene Expression Regulation, Neoplastic
Humans
Immunity
Immunology
Immunotherapy
Lymphocytes
Medical prognosis
Microsatellite Instability
Mismatch repair
Mutation
Neoplasm Staging
Neoplasms - genetics
Neoplasms - pathology
Prognosis
Sequence Analysis, RNA
Survival
Survival Analysis
Symporters - genetics
Tumors
Up-Regulation
Online AccessGet full text

Cover

Abstract Background. Solute carrier family 12 member 5 (SLC12A5) has been reported to play an oncogenic role in certain malignancies. Its prognostic roles and immune mechanisms of action in human cancers, however, remain largely unknown. Methods. Data derived from TCGA, GEPIA, and TIMER databases were utilized to delve into the expressing patterns, prognostic values, clinical significances, and tumor immunity of SLC12A5 in tumors. Additionally, the association of SLC12A5 expressions with tumor mutation burden (TMB), methyltransferases, and mismatch repairs (MMRs) was also analyzed. Results. Herein, we observed that SLC12A5 was significantly overexpressed in various malignancies, and SLC12A5 levels correlated with overall survival, disease-specific survival, and tumor stage of certain cancers. Furthermore, we noticed that SLC12A5 was distinctly associated with methyltransferases, mismatch repair proteins, TMB, and MSI in human cancers. Conclusions. SLC12A5 may act as a potential prognostic and immunological biomarker and therapeutic target for human cancers.
AbstractList Background. Solute carrier family 12 member 5 (SLC12A5) has been reported to play an oncogenic role in certain malignancies. Its prognostic roles and immune mechanisms of action in human cancers, however, remain largely unknown. Methods. Data derived from TCGA, GEPIA, and TIMER databases were utilized to delve into the expressing patterns, prognostic values, clinical significances, and tumor immunity of SLC12A5 in tumors. Additionally, the association of SLC12A5 expressions with tumor mutation burden (TMB), methyltransferases, and mismatch repairs (MMRs) was also analyzed. Results. Herein, we observed that SLC12A5 was significantly overexpressed in various malignancies, and SLC12A5 levels correlated with overall survival, disease-specific survival, and tumor stage of certain cancers. Furthermore, we noticed that SLC12A5 was distinctly associated with methyltransferases, mismatch repair proteins, TMB, and MSI in human cancers. Conclusions. SLC12A5 may act as a potential prognostic and immunological biomarker and therapeutic target for human cancers.
Solute carrier family 12 member 5 (SLC12A5) has been reported to play an oncogenic role in certain malignancies. Its prognostic roles and immune mechanisms of action in human cancers, however, remain largely unknown. Data derived from TCGA, GEPIA, and TIMER databases were utilized to delve into the expressing patterns, prognostic values, clinical significances, and tumor immunity of SLC12A5 in tumors. Additionally, the association of SLC12A5 expressions with tumor mutation burden (TMB), methyltransferases, and mismatch repairs (MMRs) was also analyzed. Herein, we observed that SLC12A5 was significantly overexpressed in various malignancies, and SLC12A5 levels correlated with overall survival, disease-specific survival, and tumor stage of certain cancers. Furthermore, we noticed that SLC12A5 was distinctly associated with methyltransferases, mismatch repair proteins, TMB, and MSI in human cancers. SLC12A5 may act as a potential prognostic and immunological biomarker and therapeutic target for human cancers.
Solute carrier family 12 member 5 (SLC12A5) has been reported to play an oncogenic role in certain malignancies. Its prognostic roles and immune mechanisms of action in human cancers, however, remain largely unknown.BACKGROUNDSolute carrier family 12 member 5 (SLC12A5) has been reported to play an oncogenic role in certain malignancies. Its prognostic roles and immune mechanisms of action in human cancers, however, remain largely unknown.Data derived from TCGA, GEPIA, and TIMER databases were utilized to delve into the expressing patterns, prognostic values, clinical significances, and tumor immunity of SLC12A5 in tumors. Additionally, the association of SLC12A5 expressions with tumor mutation burden (TMB), methyltransferases, and mismatch repairs (MMRs) was also analyzed.METHODSData derived from TCGA, GEPIA, and TIMER databases were utilized to delve into the expressing patterns, prognostic values, clinical significances, and tumor immunity of SLC12A5 in tumors. Additionally, the association of SLC12A5 expressions with tumor mutation burden (TMB), methyltransferases, and mismatch repairs (MMRs) was also analyzed.Herein, we observed that SLC12A5 was significantly overexpressed in various malignancies, and SLC12A5 levels correlated with overall survival, disease-specific survival, and tumor stage of certain cancers. Furthermore, we noticed that SLC12A5 was distinctly associated with methyltransferases, mismatch repair proteins, TMB, and MSI in human cancers.RESULTSHerein, we observed that SLC12A5 was significantly overexpressed in various malignancies, and SLC12A5 levels correlated with overall survival, disease-specific survival, and tumor stage of certain cancers. Furthermore, we noticed that SLC12A5 was distinctly associated with methyltransferases, mismatch repair proteins, TMB, and MSI in human cancers.SLC12A5 may act as a potential prognostic and immunological biomarker and therapeutic target for human cancers.CONCLUSIONSSLC12A5 may act as a potential prognostic and immunological biomarker and therapeutic target for human cancers.
Author Liao, Hong-li
Chen, Li-ya
Jiang, Yi
AuthorAffiliation Department of Pathology, Wenzhou Central Hospital, Wenzhou, Zhejiang, China
AuthorAffiliation_xml – name: Department of Pathology, Wenzhou Central Hospital, Wenzhou, Zhejiang, China
Author_xml – sequence: 1
  givenname: Yi
  surname: Jiang
  fullname: Jiang, Yi
  organization: Department of PathologyWenzhou Central HospitalWenzhouZhejiangChinawmu.edu.cn
– sequence: 2
  givenname: Hong-li
  surname: Liao
  fullname: Liao, Hong-li
  organization: Department of PathologyWenzhou Central HospitalWenzhouZhejiangChinawmu.edu.cn
– sequence: 3
  givenname: Li-ya
  orcidid: 0000-0002-4351-8809
  surname: Chen
  fullname: Chen, Li-ya
  organization: Department of PathologyWenzhou Central HospitalWenzhouZhejiangChinawmu.edu.cn
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34630736$$D View this record in MEDLINE/PubMed
BookMark eNp90cFrFDEUBvAgFbut3jxLwEtBp33JJJnMRViGti5sUbSeQyaTcVNmkprMtOx_b-puRQt6CiS_fHy8d4QOfPAWodcETgnh_IwCJWclCCpAPEMLIiteSFHCAVoArWQBlMEhOkrpBoDQmtUv0GHJMqhKsUBXS_xZ-6LR3tiIl14P2-QSDj3-um4IXXL8xd5ZPSS8mhJuQox20JMLPuF7N23w9TyGiFfjOHs3bV-i53229tX-PEbfLs6vm4_F-tPlqlmuC8OYnArRl9CVVljB-pq3NeO6lT2jzFa81V2-I13dS2iNNbmxMbWlUAJoXpJMuvIYfdjl3s7taDtj_RT1oG6jG3XcqqCd-vvFu436Hu6UZDVnosoBJ_uAGH7MNk1qdMnYYdDehjkpyiXUjIJkmb59Qm_CHPOgdopLLgTN6s2fjX5XeZx0BnQHTAwpRdsr46Zfk8wF3aAIqId1qod1qv0686f3Tz495v6Dv9vxjfOdvnf_1z8Bqxuq3Q
CitedBy_id crossref_primary_10_3803_EnM_2023_1827
crossref_primary_10_3389_fcell_2024_1466767
crossref_primary_10_1111_jcmm_18380
crossref_primary_10_3892_mmr_2024_13341
crossref_primary_10_3892_ijmm_2024_5465
crossref_primary_10_1155_2022_3119721
Cites_doi 10.1038/s41598-017-01814-0
10.1038/d41573-020-00202-0
10.1007/978-981-13-7647-4_3
10.1111/cas.14502
10.1038/s41568-019-0116-x
10.1158/0008-5472.CAN-18-3962
10.1136/ijgc-2019-000229
10.1007/s11912-018-0676-z
10.1038/s41571-018-0142-8
10.1038/cr.2016.157
10.1016/j.trecan.2018.04.001
10.1038/ni.2703
10.1158/0008-5472.CAN-17-0307
10.1038/s41586-020-2747-1
10.1016/j.cell.2020.09.001
10.1186/s12943-019-1091-2
10.1136/gutjnl-2014-308257
10.1038/s41571-019-0308-z
10.1038/s41588-018-0204-y
10.3389/fncel.2015.00386
10.1093/annonc/mdw168
10.1016/j.immuni.2019.12.011
10.1016/j.canlet.2016.01.043
10.1111/cas.12884
10.1038/s12276-019-0230-6
10.3322/caac.21590
10.1056/NEJMoa2017699
10.1038/nm.3394
10.1056/NEJMoa1500596
10.1039/D0MO00113A
10.1093/nar/gky1015
10.1177/1073858416645087
10.1016/j.it.2019.09.008
10.1016/j.cell.2015.07.022
10.1016/j.brainres.2018.12.025
ContentType Journal Article
Copyright Copyright © 2021 Yi Jiang et al.
Copyright © 2021 Yi Jiang et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0
Copyright © 2021 Yi Jiang et al. 2021
Copyright_xml – notice: Copyright © 2021 Yi Jiang et al.
– notice: Copyright © 2021 Yi Jiang et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0
– notice: Copyright © 2021 Yi Jiang et al. 2021
DBID RHU
RHW
RHX
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QL
7QO
7TK
8FD
C1K
FR3
P64
RC3
7X8
5PM
DOI 10.1155/2021/3062606
DatabaseName Hindawi Publishing Complete
Hindawi Publishing Subscription Journals
Hindawi Publishing Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Bacteriology Abstracts (Microbiology B)
Biotechnology Research Abstracts
Neurosciences Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Genetics Abstracts
Biotechnology Research Abstracts
Technology Research Database
Bacteriology Abstracts (Microbiology B)
Engineering Research Database
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList CrossRef
Genetics Abstracts

MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: RHX
  name: Hindawi Publishing Open Access
  url: http://www.hindawi.com/journals/
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1875-8630
Editor Wang, Fu
Editor_xml – sequence: 1
  givenname: Fu
  surname: Wang
  fullname: Wang, Fu
EndPage 11
ExternalDocumentID PMC8495467
34630736
10_1155_2021_3062606
Genre Journal Article
GrantInformation_xml – fundername: Natural Science Foundation of Zhejiang Province
  grantid: LY21H160011
GroupedDBID ---
0R~
36B
4.4
5GY
5RE
5VS
AAFWJ
AAJEY
ABDBF
ABJNI
ACGFS
ACIWK
ACPRK
ADBBV
ADRAZ
AENEX
AFRAH
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
DIK
DU5
EAD
EAP
EBD
EBS
EMB
EMK
EMOBN
EPL
ESX
F5P
GROUPED_DOAJ
HYE
HZ~
IAO
IHR
INH
INR
IOS
ITC
KQ8
M48
O9-
OK1
P2P
RHU
RHW
RHX
RNS
RPM
SV3
TUS
24P
AAYXX
ACCMX
CITATION
H13
.GJ
29G
53G
AAFNC
ABUBZ
ACPQW
ACUHS
ADZMO
AFRHK
AGIAB
CAG
CGR
COF
CUY
CVF
ECM
EIF
EJD
IL9
IPNFZ
MET
MIO
NPM
RIG
ZGI
7QL
7QO
7TK
8FD
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
C1K
FR3
P64
RC3
7X8
5PM
ID FETCH-LOGICAL-c448t-6f30d3e6e64f95b945ab8f424e75badf951d9f80bcec294cc9e20300a531e75d3
IEDL.DBID M48
ISSN 0278-0240
1875-8630
IngestDate Thu Aug 21 18:13:30 EDT 2025
Thu Jul 10 23:39:22 EDT 2025
Fri Jul 25 09:32:45 EDT 2025
Wed Feb 19 02:26:53 EST 2025
Thu Apr 24 23:12:13 EDT 2025
Tue Jul 01 04:22:21 EDT 2025
Sun Jun 02 18:54:51 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Language English
License This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
https://creativecommons.org/licenses/by/4.0
Copyright © 2021 Yi Jiang et al.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c448t-6f30d3e6e64f95b945ab8f424e75badf951d9f80bcec294cc9e20300a531e75d3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Academic Editor: Fu Wang
ORCID 0000-0002-4351-8809
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1155/2021/3062606
PMID 34630736
PQID 2580585662
PQPubID 2046413
PageCount 11
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_8495467
proquest_miscellaneous_2580942084
proquest_journals_2580585662
pubmed_primary_34630736
crossref_citationtrail_10_1155_2021_3062606
crossref_primary_10_1155_2021_3062606
hindawi_primary_10_1155_2021_3062606
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-00-00
PublicationDateYYYYMMDD 2021-01-01
PublicationDate_xml – year: 2021
  text: 2021-00-00
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Amsterdam
PublicationTitle Disease markers
PublicationTitleAlternate Dis Markers
PublicationYear 2021
Publisher Hindawi
John Wiley & Sons, Inc
Publisher_xml – name: Hindawi
– name: John Wiley & Sons, Inc
References 22
23
24
25
26
27
28
29
30
31
10
32
11
33
12
34
13
35
14
15
16
17
18
19
1
2
3
4
5
6
7
8
9
20
21
References_xml – ident: 22
  doi: 10.1038/s41598-017-01814-0
– ident: 2
  doi: 10.1038/d41573-020-00202-0
– ident: 17
  doi: 10.1007/978-981-13-7647-4_3
– ident: 23
  doi: 10.1111/cas.14502
– ident: 14
  doi: 10.1038/s41568-019-0116-x
– ident: 3
  doi: 10.1158/0008-5472.CAN-18-3962
– ident: 24
  doi: 10.1136/ijgc-2019-000229
– ident: 11
  doi: 10.1007/s11912-018-0676-z
– ident: 10
  doi: 10.1038/s41571-018-0142-8
– ident: 8
  doi: 10.1038/cr.2016.157
– ident: 9
  doi: 10.1016/j.trecan.2018.04.001
– ident: 31
  doi: 10.1038/ni.2703
– ident: 26
  doi: 10.1158/0008-5472.CAN-17-0307
– ident: 28
  doi: 10.1038/s41586-020-2747-1
– ident: 12
  doi: 10.1016/j.cell.2020.09.001
– ident: 13
  doi: 10.1186/s12943-019-1091-2
– ident: 25
  doi: 10.1136/gutjnl-2014-308257
– ident: 16
  doi: 10.1038/s41571-019-0308-z
– ident: 30
  doi: 10.1038/s41588-018-0204-y
– ident: 21
  doi: 10.3389/fncel.2015.00386
– ident: 5
  doi: 10.1093/annonc/mdw168
– ident: 15
  doi: 10.1016/j.immuni.2019.12.011
– ident: 6
  doi: 10.1016/j.canlet.2016.01.043
– ident: 27
  doi: 10.1111/cas.12884
– ident: 32
  doi: 10.1038/s12276-019-0230-6
– ident: 1
  doi: 10.3322/caac.21590
– ident: 35
  doi: 10.1056/NEJMoa2017699
– ident: 4
  doi: 10.1038/nm.3394
– ident: 34
  doi: 10.1056/NEJMoa1500596
– ident: 33
  doi: 10.1039/D0MO00113A
– ident: 29
  doi: 10.1093/nar/gky1015
– ident: 20
  doi: 10.1177/1073858416645087
– ident: 7
  doi: 10.1016/j.it.2019.09.008
– ident: 18
  doi: 10.1016/j.cell.2015.07.022
– ident: 19
  doi: 10.1016/j.brainres.2018.12.025
SSID ssj0012949
Score 2.2885475
Snippet Background. Solute carrier family 12 member 5 (SLC12A5) has been reported to play an oncogenic role in certain malignancies. Its prognostic roles and immune...
Solute carrier family 12 member 5 (SLC12A5) has been reported to play an oncogenic role in certain malignancies. Its prognostic roles and immune mechanisms of...
SourceID pubmedcentral
proquest
pubmed
crossref
hindawi
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1
SubjectTerms Biomarkers
Biomarkers, Tumor - genetics
Cancer
Disease Progression
DNA Mismatch Repair
Gene expression
Gene Expression Profiling - methods
Gene Expression Regulation, Neoplastic
Humans
Immunity
Immunology
Immunotherapy
Lymphocytes
Medical prognosis
Microsatellite Instability
Mismatch repair
Mutation
Neoplasm Staging
Neoplasms - genetics
Neoplasms - pathology
Prognosis
Sequence Analysis, RNA
Survival
Survival Analysis
Symporters - genetics
Tumors
Up-Regulation
SummonAdditionalLinks – databaseName: Hindawi Publishing Open Access
  dbid: RHX
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3dS8MwEA9uoPgifjudEmE-STFNk2x5HMMxxYnoBnsrbZqwgXaydYr_vZc1K24q-tj2-sFdrvf75S4XhGokoAlQaeIp32jPRggv9on2iDQATinTmtjFyd170emz2wEfuCZJ0-8pfIh2lp77V4BsAXmLEirBALOkvDMokgVU5iiX2maxEKEW9e0r9y5FnvWhpbzvo5-A5Wp95JeA095GWw4p4mZu2h20ptNdtNF1ufA91G3ihyj1WtZsE7xoLoLHBj_dtXza5PhRvwEMnOKbbIpbdhcOV_eG7eQr7s1exhN8M18fkn3so377utfqeG5zBE8Bo8o8YQKSBFpowYzksWQ8ihuGgXbrPI4SOOcn0jRIrLQCBSklNQWHJhE4HYgkwQEqp-NUHyHMFK9HPKKEAT0xRktheFwHqOJLrZjvV9DlQnGhcp3D7QYWz-GcQXAeWjWHTs0VdFFIv-YdM36Rqzkb_CFWXRgodO41DSlvEBhKQtAKOi8ug2PYbEeU6vEsl5G2eIBV0GFuz-JFARP23wYPry9ZuhCwTbeXr6Sj4bz5dgMYJQSX4_99_QnatIf5nE0VlbPJTJ8Cisnis_kY_gRnn-aL
  priority: 102
  providerName: Hindawi Publishing
Title A Pan-Cancer Analysis of SLC12A5 Reveals Its Correlations with Tumor Immunity
URI https://dx.doi.org/10.1155/2021/3062606
https://www.ncbi.nlm.nih.gov/pubmed/34630736
https://www.proquest.com/docview/2580585662
https://www.proquest.com/docview/2580942084
https://pubmed.ncbi.nlm.nih.gov/PMC8495467
Volume 2021
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwED_tQyBeEBswCmMy0nhCAcexnfgBoara1MGKYKxS36LEsbVJI4U2Bfbfc5ePbp02wUukxJcP3flyv_Od7wD2eSQKdKV5YEPvArIQQR5yF3DjEZwK6Rynzcmjz3o4lh8narIGXbfRloHzW1076ic1nl28_fPz8gMq_Pta4ZUi_z18h9AXobleh020STGp6EhexROEaYCwoHqyaMS6FPgbd68Yp3tn5BX_Pr8Ne95Mobxmkw4fwcMWTLJ-I_0tWHPlNtwfteHyxzDqsy9ZGQxIsjPW1R9hU8--HQ9C0VfsxP1CpDhnR9WcDahRR5sax2h9lp0uvk9n7KjeQlJdPoHx4cHpYBi0_RMCi05XFWgf8SJy2mnpjcqNVFmeeIkCiFWeFXgtLIxPeG6dRQZZa5xAnecZ6iWSFNFT2CinpXsGTFoVZyoTHHkrvXdGe5XHiGZC46wMwx686RiX2ra4OPW4uEhrJ0OplNictmzuwesl9Y-mqMYddPutDP5BttsJKO0mUCpUwnG2aS168Go5jLpDAZGsdNNFQ2Mov0D2YKeR5_JFkdT0-8OHxyuSXhJQXe7VkfL8rK7PnaDTifbn-f99_Qt4QKfNss4ubFSzhXuJQKfK92D909dkr57JeDwZTv4CJFH2CQ
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+Pan-Cancer+Analysis+of+SLC12A5+Reveals+Its+Correlations+with+Tumor+Immunity&rft.jtitle=Disease+markers&rft.au=Jiang%2C+Yi&rft.au=Liao%2C+Hong-li&rft.au=Chen%2C+Li-ya&rft.date=2021&rft.pub=Hindawi&rft.issn=0278-0240&rft.eissn=1875-8630&rft.volume=2021&rft_id=info:doi/10.1155%2F2021%2F3062606&rft.externalDocID=10_1155_2021_3062606
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0278-0240&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0278-0240&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0278-0240&client=summon